SBC Medical Group begins trading on Nasdaq; HeartCore guides Q3 rev $19-23M, net profit $4-8M

HeartCore Enterprises, Inc.

Go IPO client SBC Medical Group commenced trading on Nasdaq Global Market under symbol 'SBC'.
HeartCore generated $17.9M total revenue from SBC deal; $17M recognized in Q3 2024.
HeartCore holds $8M worth of SBC stock after IPO.
Q3 2024 guidance: revenue $19M-$23M, net profit $4M-$8M.
Sold $9M of warrants to a Japanese financial institution in Q1 2024; net sales $5.64M after referral fee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.